GlassScriptPhysician profile
Nancy Nieves
NPI 1104397512
$3,846.12
in general payments reported to CMS, 2019-2025
28 companies · $1,137 in 2025
The $1,137 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $18.68 · 2022: $47.01 · 2023: $1,894 · 2024: $750 · 2025: $1,137.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,760 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,760.21 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $463.94 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $444.45 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $427.97 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $408.92 | 2023-2025 | Mounjaro, Trulicity, Jardiance |
| Astellas Pharma US INC | $340.92 | 2023-2025 | Veozah |
| Amgen INC. | $237.88 | 2023-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $216.47 | 2023-2025 | Trelegy Ellipta, Shingrix |
| Pfizer INC. | $194.21 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $191.51 | 2023-2025 | |
| Exact Sciences Corporation | $166.18 | 2023-2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $104.25 | 2023-2024 | |
| Dexcom, INC. | $95.76 | 2023-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $89.04 | 2022-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $64.61 | 2024-2025 | Xifaxan |
| Corcept Therapeutics | $58.82 | 2024-2025 | Korlym |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vbi Vaccine (Delaware) INC. | $55.92 | 2023 | Prehevbrio |
| Daiichi Sankyo INC. | $40.69 | 2022-2023 | Injectafer |
| Lucid Diagnostics INC. | $38.06 | 2023-2025 | |
| Lundbeck LLC | $30.09 | 2023 | Vyepti |
| Otsuka America Pharmaceutical, INC. | $26.01 | 2023 | Rexulti |
| Sanofi Pasteur INC. | $22.22 | 2023 | |
| Janssen Pharmaceuticals, INC | $21.66 | 2023 | Xarelto |
| Inari Medical, INC. | $20.93 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Idorsia Pharmaceuticals US INC | $19.80 | 2024 | Quviviq |
| Amneal Pharmaceuticals LLC | $18.68 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $17.47 | 2025 | Zoryve |
| Tolmar, INC. | $16.02 | 2023 | |
| Esperion Therapeutics, INC. | $13.64 | 2025 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Nieves listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.